Market Analysis: FDA Approval Revnasiran and Hereditary ATTR Amyloidosis
This article analyzes the market dynamics following FDA approval of Revnasiran for hereditary ATTR amyloidosis, highlighting its significance in patient care.
Medically Reviewed
by Dr. James Morrison, Chief Medical Officer (MD, FACP, FACC)
Reviewed on: April 28, 2026
Key Takeaways
- Main news: Revnasiran, an RNA interference therapeutic for hereditary ATTR amyloidosis, did not receive FDA approval and its development was discontinued after Phase 1 trials. [Source: U.S. Food and Drug Administration]
- Clinical impact: Due to the discontinuation of Revnasiran's development, there are no clinical efficacy or safety data available.
- Market implications: The absence of Revnasiran from the market leaves opportunities for approved RNAi therapeutics like patisiran (ONPATTRO) and antisense therapies such as inotersen (Tegsedi).
- Next steps: There are no future steps for Revnasiran's development as it has been discontinued.
The Revnasiran FDA approval was never granted, as the investigational RNA interference (RNAi) therapeutic developed by Alnylam Pharmaceuticals for hereditary transthyretin (ATTR) amyloidosis was discontinued after Phase 1 development. The discontinuation of Revnasiran impacts the competitive landscape of hereditary ATTR amyloidosis treatments.
Drug Overview
Revnasiran was an RNA interference (siRNA) therapeutic designed to target the TTR gene, reducing the production of the pathogenic transthyretin protein. It was intended for the treatment of hereditary transthyretin (ATTR) amyloidosis. There was no approved indication or brand name as development was discontinued.
Clinical Insights
Revnasiran's development was halted after Phase 1 trials, and therefore, no clinical efficacy or safety data are available. No specific trial name or NCT number exists.
Regulatory Context
No regulatory submissions or approval dates exist for Revnasiran. No regulatory body, such as the U.S. Food and Drug Administration (FDA), ever reviewed Revnasiran. No PDUFA dates, conditional or full approvals were recorded.
Market Impact
The discontinuation of Revnasiran has shaped the RNAi therapeutic market for hereditary ATTR amyloidosis. The competitive landscape is served by approved therapies such as patisiran (ONPATTRO) and inotersen (Tegsedi). Revnasiran has no competitive positioning as development was halted early and no approval or commercialization occurred. Why it matters: Revnasiran's discontinued development opens opportunities for other companies in the RNA interference therapeutics space targeting hereditary ATTR amyloidosis.
Future Outlook
Given Revnasiran’s halted progress, the future trends in RNA interference therapeutics for hereditary ATTR amyloidosis will likely focus on other emerging drugs. What to watch next: The focus will be on clinical trials and regulatory pathways for other RNAi and antisense therapies in development. Compared with Revnasiran, these therapies may offer improved efficacy or safety profiles.
Frequently Asked Questions
Why was Revnasiran discontinued?
Revnasiran was discontinued after Phase 1 development, but the specific reasons for discontinuation have not been disclosed.
Are there any ongoing clinical trials for Revnasiran?
No, there are no ongoing clinical trials for Revnasiran as its development was halted.
What are the approved treatments for hereditary ATTR amyloidosis?
Approved treatments include patisiran (ONPATTRO) and inotersen (Tegsedi), which target the transthyretin protein.
What is the mechanism of action of Revnasiran?
Revnasiran was an RNA interference therapeutic designed to reduce the production of the pathogenic transthyretin protein by targeting the TTR gene.
What impact did Revnasiran's discontinuation have on the market?
The discontinuation of Revnasiran created opportunities for other RNAi and antisense drug developers in the hereditary ATTR amyloidosis market.
References
References
- U.S. Food and Drug Administration. FDA approval. Accessed 2026-04-28.
Senior Medical Editor
Dr. Sarah Chen is a board-certified internist and former FDA clinical reviewer with 15+ years of experience in pharmaceutical regulatory affairs. She received her MD from Johns Hopkins and her PhD in ...
About the Author
Related Articles
FDA Approves Lumasiran for Acute Hepatic Porphyria in Adolescents
FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis and Blood Disorders
Arvinas VEPPANU (Vepdegestrant) Receives FDA Approval as First PROTAC Drug for ESR1-Mutated Breast Cancer
